The Potential Utility of 5-HT1A Receptor Antagonists in the Treatment of Cognitive Dysfunction Associated with Alzheimer's Disease

Schechter, L.E.; Dawson, L.A.; Harder, J.A.
January 2002
Current Pharmaceutical Design;Jan2002, Vol. 8 Issue 2, p139
Academic Journal
The 5-HT1A receptor has been extensively studied over the last two decades. There is a plethora of information describing its anatomical, physiological and biochemical roles in the brain. In addition, the development of selective pharmacological tools coupled with our understanding of psychiatric pathology has lead to multiple hypotheses for the therapeutic utility of 5-HT1A agents and in particular 5-HT1A receptor antagonists. Over the last decade it has been suggested that 5-HT1A receptor antagonists may have therapeutic utility in such diseases as depression, anxiety, drug and nicotine withdrawal as well as schizophrenia. However, a very compelling rationale has been developed for the therapeutic potential of 5-HT1A receptor antagonists in Alzheimer's disease and potentially other diseases with associated cognitive dysfunction. Receptor blockade by a 5-HT1A receptor antagonist appears to enhance activation and signaling through heterosynaptic neuronal circuits known to be involved in cognitive processes and, as such, represents a novel therapeutic approach to the treatment of cognitive deficits associated with Alzheimer's disease and potentially other disorders with underlying cognitive dysfunction.


Related Articles

  • A BREAKTHROUGH IN TREATING DEMENTIA? Olszewska, Karolina // Warsaw Voice;Sep2015, Issue 9, p14 

    The article offers information on the project New non-amyloid treatment of cognitive disorders (NATCo) conducted by Polish researchers for developing drug for treatment of Alzheimer's disease. Topics discussed include serotonin receptors being target of the drug, use of drug in improvement of...

  • Cerebrolysin. Plosker, Greg L.; Gauthier, Serge // Drugs & Aging;2009, Vol. 26 Issue 11, p893 

    Cerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that has pharmacodynamic properties similar to those of endogenous neurotrophic factors. In several randomized, double-blind trials of up to 28 weeks' duration in patients with Alzheimer's disease,...

  • Idebenone: a guide to its use in Alzheimer's disease, other age-related cognitive disorders and Friedreich's ataxia.  // Drugs & Therapy Perspectives;Feb2010, Vol. 26 Issue 2, p1 

    Oral idebenone is a valuable, well tolerated and safe option for improving cognitive function and other clinical symptoms in patients with Alzheimer's disease and other age-related cognitive disorders. It has also shown some promising results in delaying the progression of neurological symptoms...

  • Dietary approach for cognitive and behavioral problems in dementia. Bhandari, Prasan R. // International Journal of Nutrition, Pharmacology, Neurological D;Oct2013, Vol. 3 Issue 4, p398 

    The article discusses a dietary approach for cognitive and behavioral problems in dementia. It describes the anti-amyloidogenic effect of a carotenoid from the stigma of the saffron flower called crocin. It also offers information on other common dietary ingredients that have a beneficial effect...

  • Monitoring Signaling by the p75NTR Receptor Utilizing a Caspase-3 Activation Assay Amenable to Small-Molecule Screening. Bradshaw, J. Michael; Nguyen, Lan; Wallace, William; Li, Calvin; Sauer, John-Michael; Bard, Frédérique; Bova, Michael P. // Assay & Drug Development Technologies;Aug2012, Vol. 10 Issue 4, p353 

    p75NTR is a neurotrophin receptor that can mediate either survival or death of neurons depending on the cell context. Modulation of p75NTR is a promising strategy to promote neuronal survival for treatment of cognitive disorders such as Alzheimer's disease. Despite years of investigation into...

  • Metalloproteinase’s Activity and Oxidative Stress in Mild Cognitive Impairment and Alzheimer’s Disease. Sagrario Martín-Aragón; Paloma Bermejo-Bescós; Juana Benedí; Emanuela Felici; Pedro Gil; José Ribera; Ángel Villar // Neurochemical Research;Feb2009, Vol. 34 Issue 2, p373 

    Abstract  Matrix metalloproteinases (MMPs) and oxidative stress have been implicated in neurological diseases such as Alzheimer’s disease (AD). Plasma MMP-2 and MMP-9 activities were assessed in Mild Cognitive Impairment (MCI) and AD subjects compared with aged-matched controls, and...

  • Reversal of memory deficits by ethanolic extract of Mimusops elengi Linn. in mice. Joshi, Hanumanthachar; Parle, Milind // Pharmacognosy Journal;May/Jun2012, Vol. 4 Issue 29, p30 

    Background: Management of cognitive disorders like dementia and Alzheimer's disease has been challenging since no potential drug is available with proved efficacy. Some nootropic drugs like piracetam, aniracetam and cholinesterase inhibitors such as Donepezil® have found to exhibit severe...

  • Current Concepts of Neurocytoprotective Therapy. Gomazkov, O.; Afanasiev, V.; Rumyantseva, S.; Stupin, V.; Silina, E.; Sokhova, O. // Neuroscience & Behavioral Physiology;Mar2013, Vol. 43 Issue 3, p374 

    This review addressed the pharmacological effects and clinical efficacies of one of the 'oldest' neurocytoprotective agents - Cerebrolysin. Experimental data identifying the molecular mechanisms of action of this agent are described in detail, along with results from clinical trials...

  • Suven begins phase-I trials for Alzheimer's drug.  // FRPT- Chemical Snapshot;11/23/2014, p3 

    The article reports on the announcement Suven Life Sciences in 2014 of the start of its Phase-I clinical trial of its new chemical entity (NCE) in the U.S. in 2014 for the treatment of cognitive dysfunction associated with Alzheimer's disease and schizophrenia. Topics covered include the comment...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics